Drug Profile
NC 2600
Latest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator Kyushu University; Nippon Chemiphar
- Class Analgesics
- Mechanism of Action Purinoceptor P2X antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for phase-I development in Neuropathic-pain in Japan (PO)
- 26 Sep 2016 Safety and pharmacodynamic data from preclinical trials in Neuropathic pain presented at the 16th World Congress on Pain (WCP-2016)
- 17 Jun 2016 Phase-I clinical trials in Neuropathic pain in Japan (PO)